Stroke, intermittent claudication, foot ischaemia, and Raynaud's phenomenon are common and disabling diseases. Compared 
Nimodipine
This calcium channel blocker has a greater antivasoconstrictive effect on cerebral than limb arteries, crosses the blood brain barrier, and may also reduce ischaemic brain cell damage. A controlled trial of 186 patients with acute ischaemic stroke, confirmed by computed tomography, observed a 70% reduction in death rate within four weeks (95% confidence interval -12% to -90%), with the death rate difference maintained at six months.' All patients in this study also received dextran and heparin. Larger studies of nimodipine are in progress. Nicardipine is another calcium channel blocker also under evaluation for treating cerebral ischaemia.
Adrenergic blockers
A study of 302 conscious patients with clinically diagnosed hemisphere strokes (few underwent computed tomography) randomised to receive atenolol (50 mg daily), slow release propranolol (80 mg daily), or placebo, all starting within 48 hours, showed no significant differences in death or disability at six month follow up, but again the 95% confidence intervals were wide.4 Larger studies with computed tomography are therefore required.
Corticosteroids
Corticosteroids may reduce cerebral oedema and were assessed in several small studies between 1956 and 1976. Two more recent randomised trials of over 100 patients found no benefit in death or disability. The first trial did not use computed tomography and had a one year follow up; the second used computed tomography and had a three week follow up.
Epoprostenol (prostacyclin) and its analogues
Intravenous infusion of prostacyclin causes systemic vasodilatation (especially in the skin) and inhibits platelet aggregation. After several small studies, a randomised controlled trial of 86 Thrombolyics Treatment with thrombolvtics risks causing cerebral bleeding and cerebral oedema, and its use is still experimental.
INTRACRANIAI HAEMORRHAGE
No medical treatment has been proved to be beneficial against intracerebral haemorrhage; a study of dexamethasone showed no benefit. Two studies of subarachnoid haemorrhage showed that the fibrinolytic inhibitor, tranexamic acid, reduced the incidence of rebleeding but increased the incidence of delayed cerebral ischaemia and did not reduce death rates.S Controlled trials of nimodipine, however, showed significant reduction in neurological deficits after cerebral vasospasm,9 Nicardipine is also under evaluation. It may be logical to combine calcium entry blockade with fibrinolytic inhibition in future studies.
PRIMARY PREVENTION OF STROKE
A recent community based study of first ever stroke caused by cerebral infarction confirmed that hypertension preceded over half the strokes. The most efficient drug treatment to prevent stroke is probably to give older hypertensive patients (with diastolic blood pressure persistently over 100 mm Hg) a thiazide diuretic.9 According to the trial of the European working party on high blood pressure in the elderly, treating 100 older hypertensive patients for two years can prevent two fatal and two non-fatal cardiovascular events, especially stroke. Treating younger patients with similar blood pressure levels is less efficient, though the MRC working party on treating mild hypertension suggested guidelines for treating younger hypertensive people who may benefit more-for example, with bendrofluazide for men aged 55-64 who smoke or with propranolol for non-smoking men. "'
The lack of suitable screening tests to indicate increased platelet reactivity, which would be analogous to measuring blood pressure, hinders the use of aspirin or other antiplatelet agents. Despite this disadvantage, two studies of aspirin treatment as primary prevention of cardiovascular events showed that fewer treated people experienced cardiovascular events, including strokes." On the other hand, long term aspirin treatment possibly increases the incidence of haemorrhagic or disabling stroke, as well as having the proved side effect of gastrointestinal bleeding.'" Recent evidence suggests that oestrogen replacement therapy may reduce the incidence of stroke in postmenopausal women.' SECONDARY PREVENTION OF STROKE About one third of patients admitted to hospital die soon after their stroke, and another third have major disability. The remaining third make a complete or good recovery, however, and it is important to establish whether drugs can reduce the risk of subsequent cardiovascular events. Although only about 150/0 of strokes are preceded by a transient ischaemic attack, such events are worrying for patients and doctors, and the value of drugs to prevent the completion of a stroke should also be considered. An overview of trials of antiplatelet treatment in patients with transient ischaemic attacks or minor ischaemic strokes (as in patients with unstable angina or myocardial infarction) showed that 1 5% fewer treated patients died and 30% fewer had non-fatal strokes or myocardial infarctions.
Aspirin (300 mg a day) appears to be as effective as any other antiplatelet treatment. Lower doses of aspirin (50-150 mg a day) might in theory have a higher ratio of benefit to risk, but there is no evidence yet that lower doses prevent secondary strokes. It is therefore inappropriate for the current British National Formulary to suggest a dose of 75 mg a day. Lower doses might reasonably be tried, however, for patients with gastric intolerance of the standard 300 mg dose that is unrelieved by using an enteric coated preparation. Doctors who do not (or cannot) institute computed tomography for patients with stroke to exclude the 10-15 % with intracranial haemorrhage should appreciate that aspirin may cause further bleeding in these patients.'4
As for other antiplatelet drugs, little evidence currently exists that sulphinpyrazone or dipyridamole are effective in preventing secondary stroke when used without aspirin, but dipyridamole is being compared with low dose aspirin in a current large study. Ticlopidine, a newer antiplatelet agent, has been assessed in two trials of prevention after a stroke or transient ischaemic attack (CATS and TASS), whose results will be published shortly. The high percentage of patients who cannot tolerate aspirin makes it necessary to evaluate other antiplatelet agents.
Another review suggested that treating hypertension in patients with transient ischaemic attacks or minor strokes may also reduce subsequent strokes by up to half.' Treatment with antihypertensives as well as aspirin should therefore be considered.
VASCULAR (MULTI-INFARCT) DEMENTIA
This continues to be a controversial subject. Vascular dementia is less common than Alzheimer's (senile) dementia, their differential diagnosis can be difficult, and assessing drugs to treat them is difficult. There is no convincing evidence that vascular drugs make an important contribution to the care ofdemented patients.
Peripheral arterial disease INTERMITTENT CLAUDICATION
In this common condition of older people, the prognosis for the legs is relatively benign and fewer than 10% progress to critical ischaemia (rest pain or gangrene). The general prognosis gives cause for concern, however, because the associated coronary other patients. This study has, however, provided a useful basis for planning trials of other interventions in patients with claudication, which might reduce their risk of vascular events. Of two smaller studies of ticlopidine in preventing vascular events in patients with claudication, one has been reportedt and the second (STIMS) is expected to be reported shortly.
The placebo group in the large PACK study underwent serial treadmill walking distance studies in several centres, and the results confirm the findings of previous studies that walking distance tends to improve spontaneouslv, noticeably, and for several months, especially if patients are encouraged to "stop smoking and keep walking." Evaluating drugs in relieving the symptoms of claudication is therefore difficult: strict selection and large numbers of patients are required. Despite the statement in the current Brtish National Fomulary that "no controlled studies have shown any improvement in walking distance," large controlled studies have shown positive results for isoxsuprine, naftidrofuryl,'-oxpentifylline,'S and ticlopidine."' Though the mean increase in walking distance compared with that in patients receiving placebo is often small, some individual patients do show impressive responses. One or more of these agents may therefore be worth trying in patients whose daily activities are severely curtailed, while the anticipated benefits of time, regular exercise, and stopping smoking are awaited. Though little evidence exists that vasodilatation in itself increases blood flow to ischaemic leg muscles, several other mechanisms (such as rheological or metabolic actions) have a sound rationale. Furthermore it seems inappropriate to have a double standard for claudication and angina pectoris, whose placebo response is also well documented. Patients are as frustrated if they cannot walk because of a sore lower half as because of a sore upper half, and doctors who discriminate at the umbilicus may hit below the belt.
The theoretical importance of blood viscosity in intermittent claudication has been substantiated by a recent controlled trial of haemodilution in selected patients with claudication who have haemodvnamicallv appropriate lesions (long stenoses) that might be expected to result in low shear stresses, under which the increased viscosity of blood may become a limiting factor in muscle blood flow. Haemodilution is not "user friendly" but should be considered in severely disabled patients with claudication who do not respond to simpler measures and have no contraindications (such as severe ischaemic heart disease).
The most obvious way to relieve claudication is to relieve haemodynamically important obstructions in major arteries. Bypass grafting carries a risk of death of 05-3%, and grafts fail progressively in time, especially in smokers. Recent alternatives in selected cases include angioplasty (balloon or laser) and treatment with thrombolvtic drugs. Recent acute onset or worsening of claudication suggests thrombosis of a stenosed artery, and angiographv may give evidence of thrombosis that has been confirmed in some cases bv reperfusion after thrombolvtic treatment. The current popularity of thrombolvtics to treat acute mvocardial infarction has promoted a renaissance of interest in applying thrombolytic treatment to subacute as well as acute limb ischaemia. " The main adverse effect is bleeding, of which the most serious manifestation is the death of about 1%// from intracranial haemorrhage (for example, from an unsuspected intracranial aneurysm). This death rate, however, is comparable with that risked by operating and may be reduced by modifications currentlv being investigated. The modifications include local infusion of the thrombolvtic agent proximal to or into the thrombus via the catheter used to show the lesion by angiography and combining thrombolvtic treatment with aspirating thrombus fragments to shorten the duration of treatment.
CRITI ICAI ISCHAEMIA This may arise acutely (because of major thromboembolism) or subacutely (caused by progressive occlusion at a critical stenosis, for example, by overlying thrombus formation). Though embolectomy, angioplastv, and bypass grafting are used as appropriate, there is also increasing interest in treatment with thrombolvtics, including local infusions proximal to or into the thrombus."1 Some evidence also exists that infusions of vasodilators such as inositol nicotinate, naftidrofuryl, and prostanoids (prostaglandin El, epoprostenol (prostacyclin, prostaglandin 12), or stable prostacyclin analogues) may relieve subacute rest pain or promote ulcer healing, or both'; however, the results of large controlled studies are awaited before treatment with vasodilators can be recommended with confidence. As with intermittent claudication, several mechanisms exist by which vasodilatation may act (table I), which can be helpful in "buying time" while patients are evaluated for surgery, angioplasty, or thrombolytic treatment. As with claudication, the main problem in trials is the response of rest pain and ulceration to placebo treatment and the passage of time.
RAYNAUD)'S D)ISEASE
The mainstays of treatment of Raynaud's disease are general measures such as keeping warm, wearing gloves (including heated gloves), and excluding causes such as drugs, vibrating tools, and diseases of the cervical ribs or connective tissue. Drug treatment should be considered for severe cases, and placebo controlled trials of nifedipine, inositol nicotinate, and prostanoids suggest that they are of benefit.2' The benefit of these vasodilators is, however, often tempered by their systemic side effects ( 
